E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

gear headHow cool is this? Shampoo for men in a quart of oil bottle!

Click the banner to get some now and tell the little lady to throw that other stuff in the trash!
Tamir Biotechnology, Inc.  
Tamir Biotechnology, Inc.
ACELLast: $0.285 ($+0.005)Volume: 10,150Last Trade: 8/5/2010 5:20:01 PM
Today

Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year
 Options
Quote |  Alerts | | Free Newsletter
 
 Detailed Quote
OTC PK:ACEL $0.285 ($+0.005 +1.7857%)
Industry: Health Sector: Biotechnology
Open: 0.285 Previous Close: 0.28
Day's High: 0.285 Day's Low: 0.252
52-Week High: 3.74 52-Week Low: 1.26
 
Volume: 10,150 Outstanding: 0
Market Cap: -
Tamir Biotechnology, Inc. Profile
Alfacell is a biopharmaceutical company, primarily engaged in the discovery and development of a new therapeutic class of drugs for the treatment of cancer and other pathological conditions. Based on Co.'s proprietary Ribonuclease or RNase technology platform, Co.'s drug discovery and development program consists of novel therapeutics developed from amphibian ribonucleases. These primordial enzymes play important roles in nature. They mediate several essential biological activities, namely, regulation of cell proliferation, maturation, differentiation and celldeath.
 Tamir Biotechnology, Inc. News & Press Releases

Alfacell Provides ONCONASE(R) NDA Submission Update
SOMERSET, N.J. , Jan. 27 /PRNewswire-FirstCall/ -- Alfacell Corporation ( ACEL ) today reported that it has conducted a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) t... [more]



Alfacell Announces Receipt of NASDAQ Panel Decision
SOMERSET, N.J. , Jan. 5 /PRNewswire-FirstCall/ -- Alfacell Corporation ( ACEL ) today announced that it received notification on January 2, 2009 that the NASDAQ Listing Qual... [more]

Alfacell Reports Financial Results for First Quarter of Fiscal 2009
SOMERSET, N.J. , Dec. 10 /PRNewswire-FirstCall/ -- Alfacell Corporation ( ACEL ) today reported its financial results for the first quarter of fiscal 2009. The company recorded... [more]

Alfacell Provides ONCONASE(R) NDA Submission Update
SOMERSET, N.J. , Dec. 5 /PRNewswire-FirstCall/ -- Alfacell Corporation ( ACEL ) today reported that the U.S. Food and Drug Administration (FDA) has scheduled a pre-NDA meeting date at th... [more]

Alfacell Receives NASDAQ Delisting Letter
SOMERSET, N.J. , Aug. 1 /PRNewswire-FirstCall/ -- Alfacell Corporation ( ACEL ) today announced that it received a NASDAQ staff determination letter on July... [more]

Alfacell Receives NASDAQ Non-Compliance Notification
SOMERSET, N.J. , July 18 /PRNewswire-FirstCall/ -- Alfacell Corporation ( ACEL ) today announced that it received a non-compliance notice from The NASDAQ Stock Market ("NASDAQ") on <... [more]

Alfacell Receives NASDAQ Non-Compliance Notification
SOMERSET, N.J., June 26 /PRNewswire-FirstCall/ -- Alfacell Corporation ACEL today announced that it received a non-compliance notice from The NASDAQ Stock Market ("NASDAQ") on June 25, 2008, that states that for the last 10 consecutive tr... [more]

Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
SOMERSET, N.J., May 28 /PRNewswire-FirstCall/ -- Alfacell Corporation ACEL today announced that the preliminary statistical analysis of data from its confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE (ranpirnase), did... [more]

Market Review: Market Review for Alfacell Corporation
Trading Markets (press release): , CA - Mar 7, 2008 March 7, 2008 Alfacell Corporation ( Nasdaq: ACEL | news | PowerRating | PR Charts ) reported its financial results for the second quarter of fiscal 2008. ...

Tax Benefit Trims Alfacell's 2Q Loss
Forbes: , NY - Mar 7, 2008 31, Alfacell ( nasdaq: ACEL - news - people ) lost $1.7 million, or 4 cents per share, from $1.9 million, or 4 cents per share, in the year-earlier period. ...

Alfacell (ACEL) Reports a Q2 Loss
StreetInsider.com (subscription): , MI - Mar 7, 2008 Alfacell Corporation ( Nasdaq: ACEL ) reports a Q2 loss of $0.04 compared to a loss of $0.04 for the same period last year. No revenues were reported. ...

Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
Genetic Engineering News (press release): Alfacell Corporation ( Nasdaq: ACEL ) today reported its financial results for the second quarter of fiscal ...

Staying at Par?
Motley Fool: Oncanase, a potential oncology product from Alfacell ( Nasdaq: ACEL ) -- at the beginning of this year. ...

Alfacell to Host Fiscal Second Quarter 2008 Financial Results ...
Genetic Engineering News (press release): Alfacell Corporation ( Nasdaq: ACEL ) today announced that it will host a conference call and Webcast at 11 am EST on Friday, ...


Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts